Publications by authors named "David Dorey"

Claim this Profile
V
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.
Peter A Leone, Alejandro Ferro, Charlotte-Paige Rolle, Sergio Lupo, Joseph McGowan, David Dorey

J Infect Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV.
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick-Sanders

Clin Pharmacol Drug Dev· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Chloe Orkin, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Parul Patel, David Dorey

Clin Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Amy G Cutrell, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Romina Quercia, David Dorey

AIDS· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Chloe Orkin, Shinichi Oka, Patrick Philibert, Cynthia Brinson, Ayesha Bassa, David Dorey

Lancet HIV· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
Miranda Murray, Antonio Antela, Anthony Mills, Jenny Huang, Hans Jäger, David Dorey

AIDS Behav· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
Miranda Murray, Federico Pulido, Anthony Mills, Moti Ramgopal, Roger LeBlanc, David Dorey

HIV Res Clin Pract· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Chloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, Vadim Pokrovsky, Edgar T Overton, David Dorey

N Engl J Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
James Demarest, Mark Underwood, Marty St Clair, David Dorey, Dannae Brown

AIDS Res Hum Retroviruses· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, David Dorey

Lancet· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Pedro Cahn, Anton L Pozniak, Horacio Mingrone, Andrey Shuldyakov, Carlos Brites, David Dorey

Lancet· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis